Condition: Gastric Cancer · Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
This study is a prospective, open label, phase II clinical study intended to include patients with locally advanced gastric adenocarcinoma who have not undergone any treatment and are eligible for surgery. The study aims to evaluate the efficacy and safety of the short course sequential radiotherapy regimen of Disitamab Vedotin combined with S-1 and Sintilimab in neoadjuvant therapy for HER2 expressing locally advanced gastric cancer.
This description comes directly from the study's public registry record.
Tao Zhang, MD · 02785871982 · 1277577866@qq.com
Zhenyu Lin, MD · 15827130393 · tojilin@gmail.com
Always discuss trial participation with your own doctor first.
| Zhang Tao | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06487429